Cellular Factories - Emerging Technologies for Fabrication of Nanomedicines?

V. Ramos, X. Turon, S. Borros

Abstract

The development of innovative nanomedicines requires the implementation of new biocompatible materials and their efficient assembly into defined nanostructures. Complex and costly synthesis of these materials can be coped with biological fabrication using microorganism factories, recombinant DNA and metabolic engineering. Modern bioprocess technologies may have the key for the implementation of tomorrow’s nanomedicines. This paper specifically focuses on the current state of the art of nanopharmaceuticals and their future perspectives.

References

  1. Boltje, T. J., Buskas, T., Boons, G.-J., 2009. Opportunities and challenges in synthetic oligosaccharide and glycoconjugate research. Nat Chem, 1(8), pp.611-622.
  2. Canelas, D. A., Herlihy, K. P., DeSimone, J. M., 2009. Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 1(4), pp.391-404.
  3. Choi, S.-hyun et al., 2004. Production of Microbial Biopolymer , Poly ( ?-glutamic acid ) by Bacillus subtilis BS 62. Agricultural Chemistry & Biotechnology, 47(2), pp.60-64.
  4. Cleland, J., Geething, N., 2012. A Novel Long-Acting Human Growth Hormone Fusion Protein ( VRS-317 ): Enhanced In Vivo Potency and Half-Life. Journal of Pharmaceutical Sciences, 101(8), pp.2744-2754.
  5. Duncan, R., 2003. The dawning era of polymer therapeutics. Nature reviews. Drug discovery, 2(5), pp.347-60.
  6. Duncan, R., Gaspar, R., 2011. Nanomedicine(s) under the Microscope. Molecular Pharmaceutics, 8, pp.2101 - 2141.
  7. Engels, B., Dahm, P., Jennewein, S., 2008. Metabolic engineering of taxadiene biosynthesis in yeast as a first step towards Taxol (Paclitaxel) production. Metabolic engineering, 10(3-4), pp.201-6.
  8. Fan, C. et al., 2010. Short N-terminal sequences package proteins into bacterial microcompartments. Proceedings of the National Academy of Sciences of the United States of America, 107(16), pp.7509-14.
  9. Ferguson, E. L., Alshame, A.M.J., Thomas, D. W., 2010. Evaluation of hyaluronic acid-protein conjugates for polymer masked-unmasked protein therapy. International Journal of Pharmaceutics, 402(1-2), pp.95-102.
  10. Ferrer-Miralles, N. et al., 2009. Microbial factories for recombinant pharmaceuticals. Microbial cell factories, 8, p.17.
  11. Flintegaard, T. V. et al., 2010. N-glycosylation increases the circulatory half-life of human growth hormone. Endocrinology, 151(11), pp.5326-36.
  12. Galic, V. L. et al., 2011. Paclitaxel poliglumex for ovarian cancer. Expert Opinion on Investigational Drugs, 20(6), pp.813-821.
  13. Garnett, M. C., Kallinteri, P., 2006. Nanomedicines and nanotoxicology: some physiological principles. Occupational medicine, 56(5), pp.307-11.
  14. Gaspar, H. B. et al., 2009. How I treat ADA deficiency. Blood, 114(17), pp.3524-3532.
  15. Goel, R. et al., 2009. Biodistribution of TNF-a-coated gold nanoparticles in an in vivo model system. Nanomedicine, 4(4), pp.401-410.
  16. Hamaguchi, T. et al., 2005. NK105, a paclitaxelincorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer, 92(7), pp.1240-1246.
  17. Hutchinson, C. R., Colombo, A. L., 1999. Genetic engineering of doxorubicin production in Streptomyces peucetius: a review. Journal of Industrial Microbiology & Biotechnology, 23(1), pp.647-652.
  18. Janke, C., Rogowski, K., van Dijk, J., 2008. Polyglutamylation: a fine-regulator of protein function? EMBO Rep, 9(7), pp.636-641.
  19. Johnson, K. P. et al., 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: Results of a phase III multicenter, double blind, placebo controlled trial. Neurology, 45(7), pp.1268-1276.
  20. Johnson, R. N., Kopecková, P., Kopecek, J., 2012. Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates. Biomacromolecules, 13(3), pp.727-35.
  21. Kim, H.-N. et al., 2009. Enzymatic synthesis of a drug delivery system based on polyhydroxyalkanoateprotein block copolymers. Chemical communications, 7345(46), pp.7104-6.
  22. Krause, H.-J., Schwarz, A., Rohdewald, P., 1985. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. International Journal of Pharmaceutics, 27(2-3), pp.145-155.
  23. Kurtzhals, P. et al., 1995. Albumin binding of insulins acylated. , 731, pp.725-731.
  24. Leonelli, F. et al., 2008. Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates. Molecules, 13(2), pp.360-78.
  25. Liu, L. et al., 2011. Microbial production of hyaluronic acid: current state, challenges, and perspectives. Microbial cell factories, 10, p.99.
  26. LoRusso, P. M. et al., 2011. Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer. Clinical Cancer Research, 17(20), pp.6437- 6447.
  27. Lopez-Berestein, G., 1986. Liposomal Amphotericin B in the Treatment of Fungal Infections. Annals of Internal Medicine, 105(1), pp.130-131.
  28. Maeda, H., 2001. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Advanced Drug Delivery Reviews, 46(1-3), pp.169-185.
  29. Mao, H. et al., 2004. Sortase-mediated protein ligation: a new method for protein engineering. Journal of the American Chemical Society, 126(9), pp.2670-1.
  30. Mross, K. et al., 2004. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemotherapy and Pharmacology, 54(6), pp.514-524.
  31. Pasparakis, G. et al., 2010. Controlled polymer synthesis-- from biomimicry towards synthetic biology. Chemical Society reviews, 39(1), pp.286-300.
  32. Pisal, D. S., Kosloski, M. P., Balu-Iyer, S. V., 2010. Delivery of therapeutic proteins. Journal of Pharmaceutical Sciences, 99(6), pp.2557-2575.
  33. Roberts, M. J., Bentley, M. D., Harris, J. M., 2012. Chemistry for peptide and protein PEGylation. Advanced drug delivery reviews, 54, pp.459-476.
  34. Sharp, P. A. et al., 2011. The Third Revolution: The Convergence of the Life Sciences , Physical Sciences and Engineering.
  35. Sheffield, W. P. et al., 2004. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. British Journal of Haematology, 126(4), pp.565-573.
  36. Shibata, H., Nakagawa, S., Tsutsumi, Y., 2005. Optimization of protein therapies by polymerconjugation as an effective DDS. Molecules, 10(1), pp.162-80.
  37. Ta, H. T., Peter, K., Hagemeyer, C. E., 2012. Enzymatic antibody tagging: toward a universal biocompatible targeting tool. Trends in cardiovascular medicine, 22(4), pp.105-11.
  38. Veronese, F., Pasut, G., 2005. PEGylation, successful approach to drug delivery. Drug discovery today, 10(21), pp.1451-8.
  39. Wagner, G. K., Pesnot, T., 2010. Glycosyltransferases and their Assays. ChemBioChem, 11(14), pp.1939-1949.
  40. Wohlfart, S. et al., 2011. Efficient Chemotherapy of Rat Glioblastoma Using Doxorubicin-Loaded PLGA Nanoparticles with Different Stabilizers. PLoS ONE, 6(5), p.e19121.
  41. Wu, W. et al., 2009. Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS nano, 3(9), pp.2740-50.
  42. Yang, S. C. et al., 2008. Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjugate chemistry, 19(6), pp.1164-9.
  43. Zhao, P., Astruc, D., 2012. Docetaxel Nanotechnology in Anticancer Therapy. ChemMedChem, 7(6), pp.952- 972.
Download


Paper Citation


in Harvard Style

Ramos V., Turon X. and Borros S. (2013). Cellular Factories - Emerging Technologies for Fabrication of Nanomedicines? . In Proceedings of the International Conference on Biomedical Electronics and Devices - Volume 1: BIODEVICES, (BIOSTEC 2013) ISBN 978-989-8565-34-1, pages 209-215. DOI: 10.5220/0004329202090215


in Bibtex Style

@conference{biodevices13,
author={V. Ramos and X. Turon and S. Borros},
title={Cellular Factories - Emerging Technologies for Fabrication of Nanomedicines?},
booktitle={Proceedings of the International Conference on Biomedical Electronics and Devices - Volume 1: BIODEVICES, (BIOSTEC 2013)},
year={2013},
pages={209-215},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0004329202090215},
isbn={978-989-8565-34-1},
}


in EndNote Style

TY - CONF
JO - Proceedings of the International Conference on Biomedical Electronics and Devices - Volume 1: BIODEVICES, (BIOSTEC 2013)
TI - Cellular Factories - Emerging Technologies for Fabrication of Nanomedicines?
SN - 978-989-8565-34-1
AU - Ramos V.
AU - Turon X.
AU - Borros S.
PY - 2013
SP - 209
EP - 215
DO - 10.5220/0004329202090215